FRIDAY, August 5, 2022 (HealthDay News) — Human papillomavirus (HPV) vaccination appears to reduce the risk of recurrence of grade 2 or greater cervical intraepithelial neoplasia (CIN2+), according to a review published online Aug. 3 The BMJ.
Konstantinos S. Kechagias from Imperial College London and colleagues conducted a systematic review and meta-analysis to investigate the risk of CIN2+ recurrence after local surgical treatment. Twenty-two studies met the inclusion criteria; Eighteen of these studies also reported data from a non-vaccinated group and were included in the meta-analysis.
The researchers found that those who were vaccinated had a lower risk of CIN2+ recurrence than those who were not vaccinated (hazard ratio 0.43). When the risk of CIN2+ recurrence was assessed for diseases associated with HPV subtypes HPV16 or HPV18, the effect estimate was even stronger (hazard ratio 0.26). Confidence in the meta-analysis ranged from very low to moderate, likely due to publication bias and study inconsistencies. The risk of CIN3 recurrence was also lower in vaccinated patients, but the uncertainty was high (hazard ratio 0.28). There was no evidence of benefit for recurrence of vulvar, vaginal and anal intraepithelial neoplasia, genital warts, or persistent and incident HPV infection.
“The results of our meta-analysis suggest that adjuvant HPV vaccination at the time of local excision in CIN may result in a reduction in the risk of recurrence of high-grade preinvasive disease,” the authors write.